JP2016516692A - ヒト免疫不全ウイルス複製の阻害剤 - Google Patents

ヒト免疫不全ウイルス複製の阻害剤 Download PDF

Info

Publication number
JP2016516692A
JP2016516692A JP2016500961A JP2016500961A JP2016516692A JP 2016516692 A JP2016516692 A JP 2016516692A JP 2016500961 A JP2016500961 A JP 2016500961A JP 2016500961 A JP2016500961 A JP 2016500961A JP 2016516692 A JP2016516692 A JP 2016516692A
Authority
JP
Japan
Prior art keywords
tert
butoxy
mmol
dimethyl
acetic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016500961A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516692A5 (cg-RX-API-DMAC7.html
Inventor
ビー・ナラシムフル・ナイドゥ
マノジ・ペイテル
ケビン・ピース
ワン・ジョンギュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2016516692A publication Critical patent/JP2016516692A/ja
Publication of JP2016516692A5 publication Critical patent/JP2016516692A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D515/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016500961A 2013-03-13 2014-03-10 ヒト免疫不全ウイルス複製の阻害剤 Pending JP2016516692A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779589P 2013-03-13 2013-03-13
US61/779,589 2013-03-13
PCT/US2014/022405 WO2014164428A1 (en) 2013-03-13 2014-03-10 Inhibitors of human immunodeficiency virus replication

Publications (2)

Publication Number Publication Date
JP2016516692A true JP2016516692A (ja) 2016-06-09
JP2016516692A5 JP2016516692A5 (cg-RX-API-DMAC7.html) 2017-04-13

Family

ID=50543303

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016500961A Pending JP2016516692A (ja) 2013-03-13 2014-03-10 ヒト免疫不全ウイルス複製の阻害剤

Country Status (6)

Country Link
US (1) US9663536B2 (cg-RX-API-DMAC7.html)
EP (1) EP2970301B1 (cg-RX-API-DMAC7.html)
JP (1) JP2016516692A (cg-RX-API-DMAC7.html)
CN (1) CN105189510B (cg-RX-API-DMAC7.html)
ES (1) ES2619708T3 (cg-RX-API-DMAC7.html)
WO (1) WO2014164428A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015123182A1 (en) * 2014-02-12 2015-08-20 Bristol-Myers Squibb Company Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
WO2015123230A1 (en) 2014-02-12 2015-08-20 Bristol-Myers Squibb Company Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication
US9409922B2 (en) * 2014-02-18 2016-08-09 Bristol-Myers Squibb Company Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
EP3152215A1 (en) 2014-02-18 2017-04-12 ViiV Healthcare UK (No.5) Limited Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
EP3116879A1 (en) 2014-02-18 2017-01-18 VIIV Healthcare UK (No.5) Limited Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
WO2015126765A1 (en) 2014-02-19 2015-08-27 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9273067B2 (en) 2014-02-19 2016-03-01 Bristol-Myers Squibb Company Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
US9637501B2 (en) 2014-02-20 2017-05-02 Viiv Healthcare Uk (No. 5) Limited Pyridin-3-yl acetic acid macrocycles as inhibitors of human immunodeficiency virus replication
CN110407674A (zh) * 2018-08-14 2019-11-05 重庆市化工研究院 4-烯丙氧基苯甲醇、合成方法及应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012033735A1 (en) * 2010-09-08 2012-03-15 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2013025584A1 (en) * 2011-08-18 2013-02-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2013134142A1 (en) * 2012-03-06 2013-09-12 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2013134113A1 (en) * 2012-03-05 2013-09-12 Bristol-Myers Squibb Company Fused pyrimidines as inhibitors of immunodeficiency virus replication
WO2014028384A1 (en) * 2012-08-16 2014-02-20 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939545B2 (en) 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
PT2054416E (pt) 2006-08-04 2011-04-06 Merz Pharma Gmbh & Co Kgaa Pirazolopirimidinas substituídas, um processo para a sua preparação e a sua utilização como medicamento
JP5450108B2 (ja) 2007-03-23 2014-03-26 アレイ バイオファーマ、インコーポレイテッド グルコキナーゼ活性化剤としての2−アミノピリジン類似体
HRP20120328T2 (hr) 2007-11-15 2012-09-30 Gilead Sciences Inhibitori replikacije virusa humane imunodeficijencije
EP2574610A1 (en) 2007-11-15 2013-04-03 Gilead Sciences, Inc. Inhibitors of human immonodeficiency virus replication
KR20100097156A (ko) 2007-11-16 2010-09-02 베링거 인겔하임 인터내셔날 게엠베하 사람 면역결핍 바이러스 복제의 억제제
CA2705338A1 (en) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
CA2781780C (en) 2009-12-23 2015-02-17 Katholieke Universiteit Leuven Novel antiviral compounds
NZ604716A (en) 2010-07-02 2014-12-24 Gilead Sciences Inc 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
MA34397B1 (fr) 2010-07-02 2013-07-03 Gilead Sciences Inc Dérivés d'acide napht-2-ylacétique dans le traitement du sida
AU2011330850B2 (en) 2010-11-15 2016-01-28 Viiv Healthcare Uk Limited Inhibitors of HIV replication
MX2013005478A (es) 2010-11-15 2013-08-29 Univ Leuven Kath Compuestos heterociclicos condensados antivirales.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012033735A1 (en) * 2010-09-08 2012-03-15 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2013025584A1 (en) * 2011-08-18 2013-02-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2013134113A1 (en) * 2012-03-05 2013-09-12 Bristol-Myers Squibb Company Fused pyrimidines as inhibitors of immunodeficiency virus replication
WO2013134142A1 (en) * 2012-03-06 2013-09-12 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2014028384A1 (en) * 2012-08-16 2014-02-20 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication

Also Published As

Publication number Publication date
WO2014164428A1 (en) 2014-10-09
US20160002263A1 (en) 2016-01-07
CN105189510A (zh) 2015-12-23
EP2970301B1 (en) 2017-01-11
ES2619708T3 (es) 2017-06-26
EP2970301A1 (en) 2016-01-20
CN105189510B (zh) 2017-05-17
US9663536B2 (en) 2017-05-30

Similar Documents

Publication Publication Date Title
US9580431B2 (en) Inhibitors of human immunodeficiency virus replication
JP2016516692A (ja) ヒト免疫不全ウイルス複製の阻害剤
AU2017290755B2 (en) Diazepinone derivatives and their use in the treatment of hepatitis B infections
JP6214657B2 (ja) ヒト免疫不全ウイルス複製阻害剤
US8791108B2 (en) Inhibitors of human immunodeficiency virus replication
EP2970274B1 (en) Inhibitors of human immunodeficiency virus replication
CA3067944C (en) Bicyclic ketone compounds and methods of use thereof
JP2024150460A (ja) 治療用化合物
US9273067B2 (en) Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
CN105008369B (zh) 人类免疫缺陷病毒复制抑制剂
US9409922B2 (en) Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
EP3152215A1 (en) Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
KR20180035908A (ko) 인간 면역결핍 바이러스 복제의 억제제로서의 이미다조피리딘 매크로사이클

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170308

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20171212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180403

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181023